podcasts Ratings /ratings/en/research-insights/podcasts/the-s-p-pharma-dose-episode-26-generic-drug-pricing-when-does-the-pain-stop- content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

The S&P Pharma Dose - Episode 26: Generic Drug Pricing - When Does the Pain Stop?


COVID-19 Impact: Key Takeaways From Our Articles


Retail Trends In August Illustrated Consumers' Resilience And Shifts In Spending


2020 Global IT Spending Outlook Improves Through COVID-19 Disruption


Credit FAQ: Bausch Health Companies Inc.: What’s The Credit Quality Following Spinoff Of Eye-Care Unit?

Listen: The S&P Pharma Dose - Episode 26: Generic Drug Pricing - When Does the Pain Stop?

The S&P Pharma Guy, Arthur Wong, shares why generic drug pricing in the U.S., which has been under increasing pressure, should begin to stabilize in 2018. However, the U.S. generic drug environment will likely remain challenging over the near term and S&P harbors longer-term concerns on the industry.

Register with S&P Global Ratings

Register now to access exclusive content, events, tools, and more.

Go Back